Tianjin Takeda Pharmaceuticals

Tianjin Takeda Pharmaceuticals is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, serving as its primary manufacturing hub in China. Established in 1994 as a joint venture and becoming fully owned by Takeda in 2010, the company focuses on the production and supply of innovative medicines for the Chinese market, particularly in oncology and gastroenterology. Key products manufactured at its state-of-the-art Tianjin facility include Vonoprazan Fumarate (Takecab) and Leuprorelin Acetate Microspheres (Enantone). The site is integral to Takeda's 'Elevate China' strategy, aiming to address significant unmet medical needs through local production and modernization. The facility is also a leader in sustainability, having achieved net-zero greenhouse gas emissions in its operations. Through continuous investment and technology transfer, Tianjin Takeda ensures the reliable delivery of high-quality therapies to millions of patients across China.